Point-of-Care Tests for HIV Drug Resistance Monitoring: Advances and Potentials.
HIV
drug resistance
point-of-care test
resource-limited setting
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
25 Jun 2022
25 Jun 2022
Historique:
received:
17
05
2022
revised:
20
06
2022
accepted:
22
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
HIV/AIDS is a global public health crisis that is yet to be contained. Effective management of HIV drug resistance (HIVDR) supported by close resistance monitoring is essential in achieving the WHO 95-95-95 targets, aiming to end the AIDS epidemic by 2030. Point-of-care tests (POCT) enable decentralized HIVDR testing with a short turnaround time and minimal instrumental requirement, allowing timely initiation of effective antiretroviral therapy (ART) and regimen adjustment as needed. HIVDR POCT is of particular significance in an era when ART access is scaling up at a global level and enhanced HIVDR monitoring is urgently needed, especially for low-to-middle-income countries. This article provides an overview of the currently available technologies that have been applied or potentially used in HIVDR POCT. It may also benefit the continued research and development efforts toward more innovative HIVDR diagnostics.
Identifiants
pubmed: 35889970
pii: pathogens11070724
doi: 10.3390/pathogens11070724
pmc: PMC9321160
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Virol Methods. 2014 Dec 15;210:36-9
pubmed: 25239368
J Clin Microbiol. 2013 Oct;51(10):3324-30
pubmed: 23903546
AAS Open Res. 2020 Sep 28;3:50
pubmed: 34036243
Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):189-93
pubmed: 1986365
Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:3668-71
pubmed: 22255135
Talanta. 2021 Aug 15;231:122378
pubmed: 33965042
Clin Infect Dis. 2010 May 15;50(10):1397-404
pubmed: 20377404
J Mol Diagn. 2015 Nov;17(6):679-88
pubmed: 26322949
J Infect Dis. 2017 Dec 1;216(suppl_9):S824-S828
pubmed: 29040621
J Mol Diagn. 2019 Jul;21(4):580-592
pubmed: 31026601
J Clin Microbiol. 2002 Apr;40(4):1413-9
pubmed: 11923366
Clin Infect Dis. 2012 Jan 15;54(2):285-93
pubmed: 22144539
Antimicrob Agents Chemother. 2003 Apr;47(4):1456-9
pubmed: 12654693
Science. 1988 Aug 26;241(4869):1077-80
pubmed: 3413476
Angew Chem Int Ed Engl. 2009;48(18):3268-72
pubmed: 19219883
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32522826
PLoS One. 2016 Jan 11;11(1):e0145962
pubmed: 26751207
Anal Biochem. 2018 Mar 1;544:64-71
pubmed: 29229373
J Clin Microbiol. 1998 Feb;36(2):569-72
pubmed: 9466779
J Clin Microbiol. 2016 Jan;54(1):220-2
pubmed: 26560533
J Clin Microbiol. 2013 Nov;51(11):3666-74
pubmed: 23985909
Lancet HIV. 2020 Feb;7(2):e104-e112
pubmed: 31818716
Lancet Infect Dis. 2016 Nov;16(11):e267-e275
pubmed: 27569762
Anal Chim Acta. 2012 May 21;727:61-6
pubmed: 22541824
EBioMedicine. 2019 Dec;50:34-44
pubmed: 31767540
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):418-27
pubmed: 18614915
Commun Biol. 2021 Feb 18;4(1):227
pubmed: 33603155
EBioMedicine. 2019 Dec;50:11-12
pubmed: 31810819
PLoS One. 2013 Aug 01;8(8):e70266
pubmed: 23936402
J Mol Diagn. 2013 May;15(3):401-12
pubmed: 23541840
Anal Chem. 2018 Jun 19;90(12):7502-7509
pubmed: 29842785
Nucleic Acids Res. 2001 Jan 15;29(2):578-81
pubmed: 11139629
Anal Bioanal Chem. 2016 Mar;408(7):1943-52
pubmed: 26781105
Chem Commun (Camb). 2010 Apr 14;46(14):2432-4
pubmed: 20379549
Arch Physiol Biochem. 2012 Oct;118(4):192-6
pubmed: 22852821
J Mol Diagn. 2012 Jul;14(4):328-35
pubmed: 22691910
Clin Chim Acta. 2006 Jan;363(1-2):71-82
pubmed: 16102740
Clin Chim Acta. 2015 Jun 15;446:241-7
pubmed: 25892676
AIDS. 2020 Jul 15;34(9):1331-1338
pubmed: 32205723
AIDS Rev. 2017 Oct-Dec;19(4):219-230
pubmed: 28182618
J Clin Microbiol. 1995 Feb;33(2):342-7
pubmed: 7714190
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):246-53
pubmed: 25140907
Nat Microbiol. 2019 Jan;4(1):46-54
pubmed: 30546093